TYK2 and neoplasm: Preclinical studies on cell lines and mouse models have reported that the application of TYK2 inhibitors, including NDI-031301 and SAR-20351, induces tumor regression in T-cell acute lymphoblastic leukemia and solid cancers with significant survival benefits (Akahane et al., 2017).